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Abstract 
The vast majority of cancers commandeer the activity of telomerase - the remarkable enzyme 
responsible for prolonging cellular lifespan by maintaining the length of telomeres at the ends 
of chromosomes. Telomerase is only normally active in embryonic and highly proliferative 
somatic cells. Thus, targeting telomerase is an attractive anti-cancer therapeutic rationale 
currently under investigation in various phases of clinical development. However, previous 
reports suggest that an average of 10-15% of all cancers lose the functional activity of te-
lomerase and most of these turn to an Alternative Lengthening of Telomeres pathway (ALT). 
ALT-positive tumours will therefore not respond to anti-telomerase therapies and there is a 
real possibility that such drugs would be toxic to normal telomerase-utilising cells and ulti-
mately select for resistant cells that activate an ALT mechanism. ALT exploits certain DNA 
damage response (DDR) components to counteract telomere shortening and rapid trimming. 
ALT has been reported in many cancer subtypes including sarcoma, gastric carcinoma, central 
nervous system malignancies, subtypes of kidney (Wilm’s Tumour) and bladder carcinoma, 
mesothelioma, malignant melanoma and germ cell testicular cancers to name but a few. A 
recent heroic study that analysed ALT in over six thousand tumour samples supports this 
historical spread, although only reporting an approximate 4% prevalence. This review high-
lights the various methods of ALT detection, unravels several molecular ALT models thought 
to promote telomere maintenance and elongation, spotlights the DDR components known to 
facilitate these and explores why certain tissues are more likely to subvert DDR away from its 
usually protective functions, resulting in a predictive pattern of prevalence in specific cancer 
subsets. 
Key words: telomerase, cancer, Alternative Lengthening of Telomeres, DNA damage response, 
immortality 
Introduction 
Human telomeres are regions of 4-15 kilobases of 
repetitive hexameric (TTAGGGn) DNA sequences at 
the ends of each chromosome  (1). They end with a 
3’-overhang that most likely folds back and invades 
its  complementary  strand  to  form  a  t-loop  (2).  A 
complex of telomere-specific shelterin proteins bind 
and cap telomeres, further preventing chromosomal 
ends  from  being  recognised  as  DNA double  strand 
breaks  (DSB)  by  the  DNA  damage  response  (DDR) 
machinery (3,4). As the lagging strands of telomeres 
are  incapable  of  being  fully  replicated  during  each 
round of cell division, telomeres undergo progressive 
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shortening  during  normal  cellular  proliferation. 
Eventually, they become so short that they trigger the 
DDR,  termed  crisis  (3,5,6).  This  normally  results  in 
replicative  senescence  and  eventually  check-
point-driven cell death, defining cellular lifespan and 
safeguarding an organism against unlimited cellular 
proliferation  and  cancer  (4,7).  The  vast  majority  of 
tumours initially lose the function of important cell 
cycle  checkpoints  such  as  p53  and  Retinoblastoma 
(Rb)  proteins  and  eventually  activate  a  telomere 
maintenance mechanism (TMM). TMMs use either the 
telomerase  enzyme  -  the  holoenzyme  remarkably 
consisting  of  its  own  ribosomal  RNA  sequence 
(hTERC)  and  a  catalytic  enzyme  (hTERT)  that  syn-
thesises new telomeric DNA from its own template 
(8),  or  telomerase-independent  Alternative  Length-
ening of Telomere (ALT) pathways (9)(10).  
During the early stages of human development, 
telomerase  is  needed  to  compensate  for  the  huge 
amount of cell divisions needed to complete embry-
ogenesis and its expression is robustly switched off at 
a later stage (11,12). At birth through to adulthood, 
the  only  cells  that  continue  the  requirement  for  te-
lomerase activity are dividing male germ cell lineages, 
specific  bone  marrow  stem  cells,  activated  lympho-
cytes, and proliferative skin and gastrointestinal cells 
(12).  However,  60-70%  of  immortalised  cell  lines 
grown in tissue culture and an estimated 85-90% of 
cancer tissue overcome this limited proliferative ca-
pacity  by  up-regulating  telomerase  activity 
(4,10,13-16).  Thus,  a  pharmaceutical  interest  in  tar-
geting  telomerase  as  an  anti-cancer  therapeutic  ra-
tionale  is  well  established.  Geron  Corporation’s  in-
travenous  GRN163L  (Imetelstat)  oligonucleo-
tide-based therapy hybridises to the template region 
of hTERC and has completed a Phase I clinical trial in 
patients with chronic lymphocytic leukaemia, multi-
ple myeloma, breast cancer and non-small cell lung 
cancer  (NSCLC)  (17).  Geron’s  most  advanced 
hTERT-based GV1001 (GemVax) vaccine designed to 
raise  immune  cytotoxic  T  cell  responses  against  a 
16-mer peptide from the active site of human hTERT 
is in Phase I & II clinical trials (in NSCLC, hepatocel-
lular carcinoma and non-resectable pancreatic carci-
noma) and in a randomized Phase III clinical trial in 
patients with locally advanced or metastatic pancre-
atic  cancer  (ClinicalTrials.gov  Identifier: 
NCT00425360) (18,19).  
However, it is important to note that i) telomer-
ase-deficient ALT tumours will not respond to these 
therapies, ii) toxic effects in blood and other telomer-
ase-utilising  regenerative  tissue  may  be  limiting 
(Phase I trials of Imeteltstat noted reversible anaemia, 
thrombocytopenia  and  neutropenia  –  although  it  is 
possible that these could be due to off-target effects or 
the concurrent standard chemotherapy used (20,21)) 
iii)  long  treatment  regimes  would  be  required  to 
gradually erode telomeres of varying lengths in par-
ticular  tumours  (22),  iv)  telomerase  inhibition  is 
known  to  have  TMM-independent  effects  on  cell 
growth and telomere length depending on whether 
hTERT or hTERC is targeted (23). Lastly, v) there is a 
significant  possibility  that  such  drugs  would  ulti-
mately select for resistant cells that activate an ALT 
mechanism (24). 
ALT  is  therefore  also  a  potentially  attractive 
drug  target  since  repression  of  ALT  in 
ALT-dependent immortal cell lines results in selective 
senescence and cell death (25). In particular, ALT in-
hibition,  by  siRNA-targeting  of  ALT  components, 
appears to result in a more rapid telomere dysfunc-
tion  (26)(10,27-29)  which  may  increase  therapeutic 
efficacy.  Furthermore,  in  the  equally  established 
pursuit  of  targeting  telomere  DNA  itself  in  cancer 
cells,  early  data from  studies  using  the  macrocyclic 
compound  Telomestatin,  which  binds  to 
G4-quadruplexes commonly formed in G-rich regions 
of DNA such as promoters and telomeres, show ef-
fective  killing  of  telomerase-positive  and  ALT  cell 
lines (30). However, regardless of issues surrounding 
overcoming  drug-like  physical  properties  of 
G4-quadruplex binders, it is not known if their mode 
of action is specific to ALT or TMMs in general since 
approximately half of all gene promoters in the hu-
man  genome  and  many  oncogenic  promoters  e.g. 
c-myc, VEGF, HIF-1a, Bcl-2, Ret, c-kit and KRAS also 
contain  G-rich  sequences  and  are  known  to  form 
G-quadruplexes in vitro (31,32) (for detailed reviews on 
G-quadruplexes see (33,34)). 
Several  caveats  to  specifically  targeting  ALT 
must be considered. It is possible that ALT-positive 
primary tumours could give rise to telomerase reac-
tivated secondary tumours and vice versa especially if 
each TMM is suppressed epigenetically rather than by 
non-functional  mutation/s.  It  has  also  been  shown 
that telomerase can be transfected into an ALT cell 
line  and  appear  active  alongside  ALT  (35).  Lastly, 
there are documented cases of tumors that appear to 
be both telomerase- and ALT-negative, although it is 
possible  that  these  may  just  be  early  tumours  that 
have not yet experienced sufficient telomere shorten-
ing to need a TMM and may simply end up sponta-
neously regressing due to an inability to engage any 
TMM. Spontaneously regressing telomerase-deficient 
Type IVS neuroblastoma may be a classic example of 
this (36,37). This review explores i) how ALT is de-
tected  in  cells  and  tissues,  ii)  unravels  the  escape 
pathways that ALT-positive cells are thought to use,  Journal of Cancer 2012, 3 
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iii) identifies the main components of ALT as poten-
tially attractive drug targets and iv) speculates why 
certain malignancies, recently highlighted in a com-
prehensive survey of ALT across >6000 samples con-
firming previously predicted patterns of ALT preva-
lence across cancers, choose ALT over telomerase re-
activation to achieve immortality. 
The ALT phenotype and ALT detection in 
cell lines and tissue 
ALT was first deduced in human cell lines from 
the fact that some telomerase-deficient lines were able 
to  be  maintained  in  culture  for  many  hundreds  of 
population  doubling  times  (38).  Later  phenotypic 
studies revealed that, unlike telomerase-positive cells, 
ALT-dependent  cells  almost  always  contain  hetero-
geneous  telomere  length  distribution  (38)  and  form 
ALT-associated ‘promyelocytic leukemia (PML) bod-
ies’  or  ‘APBs’  (13,39).  These  phenotypes  are  either 
undetectable  or  have  very  low  levels  of  activity  in 
normal  somatic  cells,  therefore  providing  valuable 
biomarkers for ALT. Here’s how these attributes are 
tested in cell lines and tissue microarrays (TMAs): 
1.  Measuring  telomere  length  is  the  definitive 
method for identifying ALT. One of the hallmarks of 
ALT is telomere length heterogeneity, ranging from 
very  long  (up  to  20kb  –  twice  as  long  as  those  in 
non-ALT  cells)  to  very  short  telomeres.  A  gradual 
erosion of telomere length in ALT+ cells is usually at 
the 50kb per cell division rate and critically short te-
lomeres  at  a  cell’s  crisis  point  are  then  thought  to 
re-stimulate  ALT  mechanism/s.  These  varied  and 
fluctuating lengths of telomeres can be measured by 
terminal restriction fragment Southern blotting, fluo-
rescence in-situ hybridisation (FISH) and single telo-
mere length analysis (STELA) on chromosomal met-
aphase spreads. These labour intensive methods can 
be  applied  to  cell  lines  and  formalin  fixed  paraf-
fin-embedded (FFPE) human tissue biopsies or TMAs 
tissues  only  with  well-preserved  genomic  material 
but are low throughput for screening large numbers 
of  compounds  for  finding  ALT  inhibitors.  Further-
more, in order to demonstrate cells can maintain te-
lomeres for sufficient periods of time, at least 20 dou-
bling times are needed in tissue culture, dramatically 
reducing  practicality  and  are  not  that  sensitive  to 
subtle TMM activities (40).  
2.  The  TRAP  (telomere  repeat  amplification 
protocol)  assay  has  been  a  long-established 
PCR-based  tool  for  measuring  telomerase  activity 
(8,41-45). This is a quantitative assay but only amena-
ble to detection in fresh or frozen cell/tissue samples, 
and  since  telomerase  requires  its  RNA  template 
component, the assay is subject to degradation due to 
RNA instability and to tissue-derived PCR inhibitors. 
This may have accounted for false-positive summaries 
of  over-all  ALT  status  across  tissues  that  has  been 
estimated to be up to 15% of all cancers. Finally, the 
requirement  for  a  positive  readout  for  ALT,  rather 
than  a  positive  readout  for  telomerase  activity  also 
renders  this  assay  not  as  suitable  as  those  directly 
measuring ALT activity. 
3. APBs are subsets of Promyelocytic leukaemia 
(PML)  bodies  that  are  punctate  regions  within  the 
nucleus where PML protein and proteins involved in 
DNA repair and replication concentrate. These bodies 
are  thought  to  be  sites  of  storage,  macromolecular 
processing and degradation and can be statically at-
tached to the nuclear matrix or mobile with varying 
sizes. APBs are defined by containing PML proteins, 
telomeric  DNA  sequences  and  telomere-protecting 
proteins  (termed  Shelterins  e.g.  TRF1  and  TRF2) 
within them. Detecting APBs by IHC and FISH is a 
simple and robust measure of ALT which can be used 
to score cell lines and TMAs. APBs vary in size with 
larger  foci  usually  increasing  during  conditions  of 
cellular  stress  and  cell  cycle  arrest  and  may  signal 
ALT cells with critically short telomeres. DNA dam-
age response (DDR) proteins are known to be present 
at  APBs  alongside  the  histone  marker  of  DSBs  - 
γH2AX. Indeed the APB foci that form using γH2AX 
and  TRF2  antibodies  have  been  termed  Telomere 
dysfunctional foci (TIFs) to reflect the fact that these 
are  recognised  as  perturbed  DNA  damaged  sites 
(Cesare and Reddel, 2010; Saharia et al 2010; Saharia 
et al, 2009).  
4. Finally, a recent report by Heaphy et al identi-
fied a 100% (19/19) perfect correlation between ALT+ 
status  and  occurrence  of  mutations  in  ATRX  and 
DAXX genes as judged by telomere FISH in pancreatic 
neuroendocrine  tumour  samples  (46).  Out  of  439 
samples across other cancers, 8/24 ALT+ cases were 
ATRX mutated and the other 16 ALT+ samples with 
no mutations detected did not have detectable levels 
of  protein.  Thus,  screening  for  ATRX/DAXX  muta-
tions/expression  may therefore be a surrogate ALT 
score  in  patient  tissues  and  may  represent  a  useful 
prognostic  and  predictive  biomarker  for  aligning 
drugs  that  inhibit  ALT  to  specific  patient  cohorts 
likely to respond. Indeed, the John’s Hopkins Univer-
sity from where the authors published this work has 
filed a patent application relating to the use of DAXX 
and ATRX mutations as diagnostic markers (46).  
Modelling the mechanisms of ALT 
Sufficiently long telomeres serve to protect the 
ends of chromosomes from DDR-mediated signalling 
whilst  also  providing  most  normal  cells  with  a  de- Journal of Cancer 2012, 3 
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fined lifespan once they reach a critically short length. 
However, their heterochromatic nature and the inter-
ference of DNA-protein complexes and higher-order 
DNA secondary structures (telomeres are G-rich re-
petitive  sequences  that  are  prone  to  form 
G-quadruplexes)  can  induce  frequent  replication 
pausing and so demand the activity of certain DDR 
pathways  under  normal  conditions.  Furthermore,  a 
fork stalled in telomeric repeats cannot be rescued by 
a converging fork since telomeres are replicated in a 
unidirectional  way.  Therefore,  telomerase-proficient 
cells utilise one or more forms of homologous recom-
bination (HR)-mediated replication fork resolution. In 
ALT  cells  without  functioning  telomerase,  HR  in 
various  forms  (template-driven  recombina-
tion-mediated  DNA  replication,  and/or 
break-induced  DNA  replication  (BIR)  –  pathways 
commonly  used  in  DDR  to  resolve  stalled  and  col-
lapsed replication forks) - has been modelled to prin-
cipally operate not only to resolve paused replication 
forks but to maintain and elongate telomeres. HR has 
only been studied in ALT cells under abnormal con-
ditions in which yeast, mouse and human cell lines 
have been genetically modified so it is difficult to as-
sess how ALT is switched on pathologically. Howev-
er, much has been learned over the past decade about 
the roles of the components of DDR that seem to be 
utilised  in  telomerase-positive  and  telomer-
ase-negative  cell  lines.  Without  telomerase  or  other 
telomere-capping/protecting  (shelterin)  components 
present, ALT is likely an unbalanced process of un-
regulated homologous telomere recombination events 
counteracting telomere shortening by using templates 
from the same telomere, a sister chromatid telomere 
or  other  chromosome,  or  extrachromosomal  t-circle 
DNA  common  in  ALT  cells  (10)  to  sustain  cellular 
survival indefinitely. 
The first evidence that ALT mechanisms involve 
recombination  processes  came  from  studies  of  Sac-
charomyces cerevisiae strains deficient in components of 
telomerase (TLC1 or EST1) (47,48). Most of these cells 
died but some clones emerged and were called type 1 
or type 2 survivors. Both were found to depend on 
RAD52  since  double  knock-outs  were  unviable. 
RAD52 is essential for double strand break repair by 
homologous  recombination.  Interestingly,  rare  colo-
nies from the double-knockout (tlc1/rad52) strain are 
rescued by also knocking out EXO1 (Maringele and 
Lydall 2004) revealing a possible inhibitory function 
of EXO1 in these ALT strains. Further and stronger 
evidence  for  a  recombination-based  mechanism  for 
ALT came from studies using plasmid integration into 
one telomeric region. The tagged DNA was seen to 
transfer from one telomere and increased in number 
to other chromosomal ends after a number of cell di-
visions (49). 
A variety of recombination-based models have 
now been proposed to describe how telomeres can be 
maintained  and  extended  without  functional  te-
lomerase activity (Figure 1 A and B). Unequal telo-
meric  sister  chromatid  exchange  (T-SCE)  has  been 
suggested to facilitate ALT (Figure 1B). This is sup-
ported by the fact that T-SCE is elevated in ALT+ cells 
as measured by CO-FISH (50). However, this model 
has  come  under  scrutiny  due  to  the  fact  that  there 
would not be any net gain in telomere length since 
one sister would elongate at the expense of the other. 
It is has therefore been suggested that perhaps if all 
the elongated telomeres were to be segregated into the 
daughter cell at the expense of the parental cell, une-
qual recombination might produce a net gain for the 
next generation. Another model has been suggested to 
get round this issue which proposes that break-induce 
replication (BIR) could do the job (Figure 1A) (51). BIR 
is  a  repair  mechanism  that  synthesises  DNA  up  to 
many kilobases away from a break site using a ho-
mologous  donor  template  (in  this  case  telomeric 
DNA) (see Figure 1A). As is seen in normal prolifera-
tive somatic cells, ALT cells are also characterized by 
the presence of extrachromosomal linear and circular 
telomere  DNA  molecules.  The  extrachromosomal 
t-circles  can  in  principle  be  utilized  as  homologous 
templates  for  HR-driven  telomere  elongation  or 
simply  undergo  rolling-circle-replication,  both 
mechanisms envisaged to facilitate ALT (Figure 1C). 
Recent evidence suggests that the latter mecha-
nism of ALT is used in normal somatic cells in a bal-
anced and controlled manner (52). Telomere shorten-
ing in normal cells not only occurs by gradual attrition 
but also by a faster form of telomere trimming (TT, 
also  known  as  telomere  rapid  deletion  –  TRD)  (52) 
and this occurs when HR resolves t-loops into t-circles 
and  much  shortened  linear  telomeres.  It  has  been 
proposed that this level of activity is increased in ALT 
cells in which TT is counteracted by elevated levels of 
HR-mediated  telomere  elongation.  This  would  ex-
plain the drastically varied length of telomeres and 
increased detection of t-circles in ALT cells and sug-
gests that subtle imbalances occurring in the regula-
tion of TT occurs between mortal and immortal states.  
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Figure 1. Proposed mechanisms of ALT. A) Break-induced replication. a and b models differ in timing of the lagging 
strand synthesis but both result in newly synthesized G and C rich strands on the recipient telomere without loss from the 
donor telomere. c shows a unidirectional replication fork establishing and following Holliday Junction resolution both donor 
and recipient telomeres experience semi-conservative replication. B) Telomeric-Sister Chromatid Exchange and C) Rolling 
circle and t-circle formation after t-loop resolution providing a linear DSB for subsequent HR-mediated invasion into 
homologous templates. 
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DNA damage response (DDR) components 
- roles in telomerase-positive and negative 
cells 
Many proteins  with specific roles  in  signalling 
global  DNA  damage  and  DNA  repair  have  been 
shown  to  locate  and  function  at  telomeres  in  te-
lomerase positive and negative cell lines (53) and im-
plicated in telomere length homeostasis and chromo-
some end protection (for a detailed review see (54). 
Since  it  is  known  that  persistent  DNA  damage  can 
elicit enhanced and deregulated DNA repair activity 
in cancer cells (55), it seems likely that recruitment of 
the DDR machinery in ALT cells represents a more 
subversive and unregulated form of activity at telo-
meres. However it must be stressed that, in fact, the 
roles  of  many  of  the  components  of  DDR  during 
normal TMMs still remain poorly understood.  
DNA damage signalling 
In  telomerase-positive  cells,  experimental  sup-
pression of the proteins known to facilitate telomere 
capping and mask the presence of a DSB at telomeric 
ends (termed Shelterins e.g. TRF2 and in some studies 
POT1) triggers a DDR. This is typified by ataxia tel-
angiectasia  mutant  (ATM)  kinase  au-
to-phosphorylation at S1981 – the master signaller for 
DSB repair; phosphorylation of H2AX (γ-H2AX) – the 
amplification signal for DSBs on chromatin and the 
recruitment of DNA repair factors including 53BP1, 
MDC1, Rad17, MRN complex (MRE11, RAD50, NBS1) 
and Rif1 (56,57). These telomeric sites are known as 
telomere dysfunction-induced foci (TIFs) and signal 
the presence of DSBs at chromosomal ends. Shortly 
afterwards cellular senescence and apoptosis ensues 
in  a  p53  and  Rb-dependent  manner.  These  experi-
mentally forced observations suggest that this occurs 
naturally  in  somatic  and  cancer  cells  that  approach 
stages of critically shortened telomeres. It is not sur-
prising therefore that the majority of ALT cell lines 
and  tumours  lack  normal  p53  and  Rb  tumour  sup-
pressor  functions  that  would  normally  trigger  cell 
death in response to persistent DSBs (58-60).  
Studies  show  that  ATM  and  PARP1-mediated 
DNA damage signalling is critical to the induction of 
cell death in cells with critically shortened telomeres 
and inhibition of PARP activity leads to the extension 
of  cellular  lifespan  (61).  In  telomerase-positive  cells 
with shortened telomeres or in ALT cells, the phos-
phorylated form of TRF2 - one of the telomere shel-
terin  proteins  -  concentrates  on  telomeres  and  it  is 
known  that  ATM  catalyses  this  (56,57).  However, 
since TRF2 is known to suppress the function of ATM 
at telomeres, the precise role of ATM is currently un-
clear. The individual roles of PARP1 and PARP2 at 
telomeres, which normally have roles in signalling the 
presence of single strand breaks in the genome, is also 
unclear. PARP1 and PARP2 are sporadically detected 
at  normal  telomeres  and  shortened  ones  and  can 
poly-ADP-ribosylate TRF2 which also removes TRF2 
from telomeres, possibly allowing access to DNA re-
pair proteins. PARP1 has been reported to colocalise 
with TRF2 in a telomerase-positive cell line, whereas 
PARP2 was shown to colocalise with TRF2 in an ALT 
cell line (62).  
MRE11, RAD50, NBS1 (MRN complex)  
Recruitment  of  MRN  is  an  early  DNA  repair 
event  at  shortened  telomeres  in  telomerase-positive 
and  negative  cell  lines  and  these  proteins  were  the 
first to be identified as necessary for ALT-mediated 
telomere  elongation  (10,63).  This  complex  tethers 
DNA ends, facilitates 5’ to 3’ resection of the DNA 
ends to create 3’ overhangs for strand invasion nec-
essary for HR (64) and it has been suggested that this 
activity  stabilises  telomere  loop  formation  (54).  In 
ALT cell lines, MRN locates in APBs and in turn re-
cruits  BRCA1.  MRN  is  also  required  for 
ATM-mediated phosphorylation of TRF1 and its dis-
sociation from telomeres in ALT and non-ALT cells, 
indicating  MRN’s  involvement  in  facilitating  HR 
events  at  shortened  telomeres  (65).  Inhibiting  MRN 
function  by  transient  or  long-term  repeated  siRNA 
transfection against either protein or over-expression 
of SP100 (a PML protein), results in telomere short-
ening but only to a certain length after prolonged in-
hibition when telomeres remained stable (63,66). This 
resulted in viable cell line progeny thereafter and may 
reflect either redundant pathways stepping in or in-
complete MRN depletion. 
Non-homologous end-joining (NHEJ) 
DNA-PK,  which  consists  of  DNA-PKcs  and 
Ku70/80 subunits, interacts with telomerase, cataly-
ses NHEJ and represses normal telomeric HR activity 
– the predominant pathway suggested to be involved 
in ALT as previously discussed (67). Celli et al con-
clude that mammalian chromosome ends are highly 
susceptible  to  HR  and  NHEJ  together  with 
TRF1/TRF2 functions to repress HR-mediated sister 
chromatid  exchanges  operating  in  ALT.  Likewise, 
defects in HR facilitators like BRCA1 and BRCA2 have 
been reported to up-regulate NHEJ and this seems to 
be true at telomeres too as BRCA1 and BRCA2 defi-
cient  cells  display  gross  chromosomal  end-end  fu-
sions and instability (68). BRCA1 is known to regulate 
telomerase  via  its  transcriptional  regulation  activity 
and  it  colocalises  with  TRF2  in  telomerase-positive  Journal of Cancer 2012, 3 
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cell lines and within APBs of ALT cells, although its 
role in ALT is unclear since expression of a dominant 
negative mutant of BRCA1 results in increased telo-
mere  length  in  telomerase-positive  cells  but  not  in 
ALT cells (69).  
The formation of t-circles in ALT cells depends 
on  recombination  proteins  X-ray  repair 
cross-complementing 3 (XRCC3), NBS1 and Ku70/80 
and  down-regulation  of  either  one  of  these  factors 
causes a decrease in the levels of t-circles and growth 
suppression in these cells (70). Since XRCC3 is a pro-
tein that forms a complex with the Rad51 paralogue 
Rad51C  in  promoting  HR  (71)and  the  Ku  proteins 
facilitate NHEJ, it  seems  that a subtle and complex 
system involving both HR and NHEJ DSB pathways 
operate in t-circle formation. This complexity is high-
lighted by the fact that although Ku70/80 and NHEJ 
is known to be involved in telomerase-positive TMM, 
Li et al from Reddel’s lab showed that Ku70/80 de-
pleted human SAOS2 cells did not display the telo-
mere  deletions  observed  in  telomerase  positive  hu-
man cells lacking Ku70/80 and did not display any 
significant  difference  in  the  overall  distribution  of 
telomere  signals,  nor  any  increase  in  chromosomal 
instability compared to control ALT cells (70). Only 
t-circle  depletion  was  noted,  highlighting  the  pre-
dominant role of NHEJ in this particular mechanism 
of ALT. As mentioned earlier, recent evidence from 
Reddel’s  lab  suggests  that  t-circle  formation  results 
from the rapid telomere trimming (TT) process asso-
ciated  with  telomere  shortening  in  telomerase 
–positive  but  more  starkly  in  telomerase-negative 
ALT cells (52). In agreement with studies showing a 
role for XRCC3 in t-circle formation, Pickett et al also 
noted  that  XRCC3  depletion  resulted  in  an  almost 
complete loss of t-circles as measured by 2D-gel elec-
trophoresis. However, GEN1 depletion did not cause 
a reduction, the putative Holliday Junction resolving 
HR protein, further supporting a model that describes 
only the involvement NHEJ and separate activities of 
certain  HR  components/subpathways  in  facilitating 
ALT. 
Homologous recombination (HR)  
Many DNA repair proteins involved in HR are 
found at normal and dysfunctional telomeres but are 
particularly active in ALT, as previously discussed. In 
addition  to  HR  components  like  Rad52  and  MRN 
highlighted  already,  BLM  is  one  of  five  known 
ATPase-driven RecQ family helicases that possesses 
3-5’  DNA  unwinding  activity,  Holliday  Junction 
branch migration and single stranded DNA annealing 
activity.  These  activities  are  required  for  resolving 
stalled and collapsed replication forks and this may be 
operative in advance of or behind a telomeric replica-
tion fork. In ALT cells, BLM is known to colocalise 
with TRF1 and TRF2 at telomeres in S-phase which 
supports such a function. WRN is another RecQ hel-
icase  which  possesses  exonuclease  activity  and  can 
interact  with  DNA-PKcs,  RPA,  MRN  and  Rad51  in 
response to DSBs. WRN normally functions to repress 
inappropriate  recombination  such  as  T-SCE  impli-
cated in ALT and is thought to unwind DNA to in-
fluence telomerase access to the 3’ overhang at the end 
of telomeres. However, WRN is also found in APBs in 
ALT cells alongside TRF1 and TRF2 in S-phase where 
it  is  thought  T-loops  require  resolution  to  promote 
telomere elongation. Knocking down HR components 
including Rad51D, MUS81, BLM or FANCA/D2 by 
RNAi dramatically shortens telomeres in ALT+ cells 
and  is  associated  with  reduced  cell  survival 
(26)(10,27-29).  RTEL  is  a  DNA  helicase  thought  to 
operate with BLM and Mus81 in resolving recombi-
nation intermediates and was first cloned by Ding et 
al in 2004 and named Regulator of Telomere length 
since Rtel(-/-) embryonic stem cells showed telomere 
loss  and  displayed  many  chromosome  breaks  and 
fusions  upon  differentiation  in  vitro  (72).  It  is  cur-
rently  unknown  if  RTEL  functions  in  telomer-
ase-deficient  cells  but  this  would  not  be  surprising 
considering  the  fact  that  other  RecQ  helicases  have 
associated functions in ALT. 
Nucleases involved in telomere maintenance 
and ALT 
Since  MRE11  is  intricately  involved  in  ALT 
mechanisms  and  is  known  to  regulate  NHEJ  and 
BRCA1 activity during HR at stalled replication forks 
(HR) (73-75), it would be interesting to know if other 
DSB repair components that are particularly associ-
ated with resolving stalled and collapsed DNA repli-
cation forks are associated with telomeric DNA. For 
instance, Metnase and FAN1 are nucleases that facili-
tate these replication processes (76-79) and it is con-
ceivable  that  such  activities  could  promote 
ALT-dependent TMMs. Other DNA repair nucleases 
such as ERCC1/XPF, Mus81 and FEN1 are known to 
operate at telomeres. ERCC1 and its partner nuclease 
XPF is responsible for cleaving the 5’ end of bubble 
structures  present  after  nucleotide  excision  repair 
initiates  DNA  unwinding  of  damaged  DNA. 
ERCC1/XPF  also  cleaves  the  G-strand  overhangs 
present at uncapped telomeres which generate sub-
strates for NHEJ in telomerase-positive cells and it is 
thought that ERCC1/XPF prevents  incorrect recom-
bination  during  chromosome  division.  This  is  sup-
ported by studies showing dividing ERCC1/XPF de-
ficient  cells  accumulating  small  pieces  of  telomeric  Journal of Cancer 2012, 3 
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DNA  called  telomeric  DNA-containing  double 
minutes  (TDMs)  which  result  from  recombination 
between telomeres and similar sequences elsewhere 
on a chromosome (80).  
Mus81, FEN1 and WRN (a RecQ helicase which 
also possesses nuclease activity) are structure-specific 
nucleases known to function in ALT and function in 
lagging-strand DNA replication, HR and the restart of 
stalled replication forks. Both FEN1 and MUS81 have 
been found to localize to telomeres in ALT cells dur-
ing the G2 phase when HR of telomeric DNA is more 
likely to occur and are known to be required for te-
lomere  stability  in  ALT  cells  (27).  Knocking  down 
MUS81 or FEN1 by RNAi dramatically shortens te-
lomeres in ALT+ cells and is associated with reduced 
cell survival (26)(10,27-29). Since MUS81 is an endo-
nuclease that cleaves various DNA substrates during 
HR and is required for the survival of cells undergo-
ing aberrant replication and recombination (81-83), it 
is not surprising that studies show a role for MUS81 in 
ALT.  FEN1  is  another  structure-specific  endo-  and 
exonuclease  that  preferentially  cleaves  5’-flap  DNA 
substrates and is therefore required for the final steps 
of long-patch base excision repair which resolves sin-
gle strand breaks and base lesions (84). It is also active 
in normal DNA replication where it processes Oka-
zaki fragments on the lagging DNA strand (85). Since 
we know telomeres can be dramatically shortened by 
trimming, loss of Mus81, FEN1 or WRN may acceler-
ate this process as cells lose the ability to resolve dif-
ficulties  encountered  during  DNA  replication.  This 
may  be  particularly  pertinent  at  telomeres  of  te-
lomerase-deficient cells in which G-rich quadruplexes 
are especially difficult to replicate. FEN1 and WRN 
directly interact in lagging strand replication, HR and 
the  restart  of  stalled  replication  forks  (86)  and  the 
FEN1/WRN telomere-loss phenotype can be rescued 
by exogenously expressing telomerase (87). However, 
WRN  promotes  t-circle  formation  in  TRF2-positive 
ALT cells and associates with other telomere shelterin 
proteins  and  in  APBs  (88-90),  but  WRN  deficiency 
leads,  in  fact,  to  stimulation  of  ALT  in  telomer-
ase-negative mouse cells (91). This suggests that WRN 
functions in telomerase-positive cells to control reso-
lution  of  perturbed  replication  forks  but  restricts 
HR-mediated  processes  required  for  ALT-mediated 
telomere elongation.  
Structural maintenance of chromosome pro-
teins in ALT 
Inter-twinings  between  sister  chromatids  are 
produced by the DNA replication process and since 
replication  forks  connect  sister  chromatids,  incom-
plete DNA replication impairs chromosome segrega-
tion. The SMC5/6 SUMO E3 ligase complex is one of 
three structural maintenance of chromosome (SMC) 
complexes within eukaryotic cells which function in 
relieving these torsional stresses by post translational 
modification of proteins including those involved in 
telomere capping (92). Since replication fork stalling is 
common at telomeres, a number of studies associate 
Smc5/6  with  repair  of  stalled/collapsed  replication 
forks especially in telomerase-defective ALT cells (92). 
Potts and Yu reported a role for the SMC5/6 complex 
in the maintenance of telomeres in human ALT cells 
(93). Smc5/6 depletion in ALT cells inhibits telomere 
recombination, causing telomere shortening and cell 
senescence.  These  studies  uncovered  a  role  for  the 
complex in sumoylating components of the telomere 
shelterin complex, including TRF1, TRF2, RAP1, and 
TIN1, and facilitating telomere recruitment or reten-
tion within APBs. More recently, Chavez et al utilized 
S. cerevisiae to determine the roles of sumoylation in 
telomerase-deficient mutants during senescence and 
demonstrated  that  sumoylation-deficient  telomer-
ase-null cells senesce at an elevated rate (94). Senes-
cent cells deficient in SMC5/6-mediated sumoylation 
exhibited elevated levels of recombination intermedi-
ates selectively at their telomere ends and the authors 
conclude  that  this  may  serve  to  ensure  the  faithful 
completion of template switch recombination. Thus, 
Smc5/6  appears  to  counteract  accumulation  of  HR 
structures at telomeres in senescing telomerase nega-
tive yeast cells (92). 
Epigenetic regulation at telomeres and in 
ALT 
Telomeres  are  generally  tightly  packed  hetero-
chromatic regions of the genome, and are less active 
in  transcription  than  the  more  open  and  transcrip-
tionally active euchromatic regions that usually rep-
licate first in S-phase of the cell cycle (95). Thus, telo-
meres  are  enriched  with  histone  modifications  (e.g. 
methylation of H3K9, K27, K20) that remodel chro-
matin to promote tighter conformations that are more 
silent  and  protected.  Specifically,  tri-methylation  of 
histone  H3K9  (H3K9me3)  by  Suv39H1/2  methyl-
transferases  facilitates  heterochromatin  Protein  -1 
(HP1)  to  promote  transcriptional  silencing.  Murine 
SUV39H1/2  deficiency  and  subsequent  loss  of 
H3K9me3  at  telomeres  respectively,  results  in  telo-
mere  elongation  (96).  Likewise,  over-expression  of 
Dot1  (Disruptor  of  Telomeres-1  discovered  in  yeast 
with known homolog in humans), results in hyper-
methylated  H3K79  at  telomeres  and  also  results  in 
telomere elongation (95-97). 
DNA itself can be methylated in heterochromatic 
regions  which  tend  to  be  rich  in  CpG  dinucleotide  Journal of Cancer 2012, 3 
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sequences  and  DNA  methyltransferases  (DNMT3A 
and  B)  perform  these  functions  following 
semi-conservative DNA replication. Mouse deficient 
in  DNMT1  or  3A/B  show  loss  of  telomere  CpG 
methylation  and  also  display  elongated  telomeres. 
However  unlike  in  humans,  only  mouse  telomeric 
DNA has been shown to be rich in CpGs (98). SIRT1 is 
the human homolog of yeast Sir2 deacetylase (type III 
histone  deacetylase),  a  component  of  the  silent  in-
formation  regulator  (SIR)  complex  encompassing 
Sir2/Sir3/Sir4. Increasing evidence suggests a major 
role  for  SIRT1  in  DDR.  SIRT1  is  recruited  to  the 
chromatin  upon  different  DNA  damage  insults, 
where it promotes efficient repair of DSBs by HR (99). 
SIRT1  deacetylates  WRN  (100)(101,102)  and  Nbs1 
(103,104) and in so doing inhibits Nbs1 phosphoryla-
tion  and  modulates  its  S-phase  checkpoint  activity 
(105).  Yeast  Sir2  is  recruited  to  telomeres  through 
Rap1  and  this  complex  spreads  into  subtelomeric 
DNA  via  histone  deacetylation.  Human  SIRT1  has 
been  shown  to  be  a  positive  regulator  of  telomere 
length in vivo and attenuates telomere shortening in 
telomerase-positive  cells  (106).  It  is  currently  un-
known if Sirtuins are involved in ALT, however, due 
to its promotery roles in HR, it would not at all be 
surprising. 
As mentioned earlier, Heaphy et al identified a 
100%  (19/19)  correlation  between  ALT+  status  and 
occurrence of mutations in ATRX and DAXX genes in 
pancreatic neuroendocrine tumour samples (46). Out 
of 439 samples across other cancers 8/8 ALT+ cases 
were ATRX mutated and a further 16 ALT+ samples 
had no detectable ATRX/DAXX protein. Exons 2-19 
of  ATRX  were  also  homozygously  deleted  in  the 
prototypical ALT+ cell line U2OS and this produced 
no  detectable  ATRX  protein  by  immunolabeling. 
ATRX is a member of the SWI/SNF family of chro-
matin remodelers and possesses ATPase-driven DNA 
helicase  activity.  This  unwinding  function  may  be 
particular  active  at  telomeres  since  recent  studies 
show a cell cycle regulated role for ATRX in hetero-
chromatin  assembly  at  repetitive  G-rich  regions. 
These studies revealed that ATRX and DAXX associ-
ated with the histone variant H3.3 and shown to be 
required for the localization of H3.3 at telomeres and 
for  the  repression  of  telomeric  RNA  in  mouse  em-
bryonic  stem  cells  (107-109).  Precise  roles  of  ATRX 
and DAXX in ALT however are currently unknown. 
The choice between ALT and telomerase 
reactivation in cancer 
Since ALT is well known to be enriched in sar-
comas, it has been suggested that ALT tends to occur 
in cells of mesenchymal origin in which perhaps te-
lomerase may be more tightly controlled (110). Recent 
experimental  evidence  supports  this  notion.  Domi-
nant  negative  mutant  telomerase  transfection  in 
bladder T24 cells resulted in a switch towards ALT (as 
measured by APB foci) after the 27th passage in cul-
ture and this was associated with a change in gene 
expression and morphology concomitant with epithe-
lial to mesenchymal transition (EMT) (111), a transi-
tion  common  during  disease  progression.  Sarcomas 
are  cancerous  tumours  generally  of  mesenchymal 
origin and form in the connective tissues of muscle, 
tendon, fat, blood vessels, or other soft tissues of the 
body (lymph nodes, nerves, and tissues around joints) 
with the legs, stomach, arms and trunk being the most 
common sarcoma sites (See Figure 2). However, ALT 
is also found commonly in certain types of CNS tu-
mors, neuroendocrine tumors and testicular germ cell 
tumors. Thus, it may not be so much that ALT is a 
mesenchymal trait per se, rather it may just be difficult 
for most cancers of epithelial tissues to engage ALT 
(10). It is tempting to speculate that as mesenchymal 
connective tissue originates from the highest embry-
onic potential of stem cells (112) and that telomerase 
activity is highly active in early mammalian embryo-
genesis (11,12), the robust silencing of telomerase that 
follows upon completion of embryogenesis may per-
sist  much  more  strongly  in  mesenchymal  tissue 
through  to  adulthood  than  other  tissues  that  never 
required such strong silencing. 
It  was  reported  that  telomerase  is  actively  re-
pressed at the chromatin level in ALT cell lines (113). 
Later, the same group uncovered a hiearchical gene 
cluster of 297 up and down regulated genes from a 
global gene expression profile of mesenchymal lipo-
sarcoma cell lines and tumour tissue that may func-
tion  to  repress  telomerase  activity  and  activate  an 
ALT  pathway  (114).  Lower  c-Myc  activity  in 
ALT-positive cells was one gene highlighted, which is 
consistent with the fact that c-Myc is a known hTERT 
transcriptional  activator  (115).  It  would  be  particu-
larly interesting to know if a common ALT gene sig-
nature, if one exists across all ALT tumours, together 
with  certain  epigenetic  imbalances  that  might  be 
prevalent in ALT tumours, may commonly enhance 
or  bias  towards  HR-mediated  responses  to  stalled 
replication forks or DSBs. 
Recent  evidence  suggests  that  cancer  cells  just 
entering the point of crisis with some remaining long 
telomeres  present  on  their  chromosomes  are  more 
likely  to  undergo  ALT  than  telomerase  activation 
(116).  This  is  based  on  the  observation  that  longer 
telomeres in yeast type II survivors (good models for 
human ALT sharing similar characteristics) are pref-
erential  substrates  for  recombination.  The  authors  Journal of Cancer 2012, 3 
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speculate  that  mutations  in  cancer  cells  that  cause 
crisis  with  remaining  long  telomeres  will  drive  an 
immortal route via ALT. It would be interesting to see 
if ATRX/DAXX mutations, recently identified to track 
100% with ALT (46,117), are indeed associated with 
longer telomeres at the ends of some of the chromo-
somes in these cells. 
Disease linkage 
Many  studies  across  various  tumour  biopsies 
over  the  past  two  decades  have  culminated  in  the 
estimation that 85-90% of all human tumours utilise 
telomerase  activity  (10,14,40,118-123).  However,  the 
presence of ALT in tumours has not been extensively 
examined across a large tissue array under the same 
assay conditions. Recently, an ambitious survey ana-
lysed over 6000 tissue samples scoring for ALT using 
FISH to probe for APB foci (124,125). Overall, 3.7% of 
tissues  in  that  study  were  determined  to  be 
ALT-positive  which  is  lower  than  previously  esti-
mated. However, despite  this  large study, ALT has 
not been screened within large enough cohorts within 
individual cancer subtypes to give an overall accurate 
estimation of ALT across disease and this will require 
further screening at centres where sufficient biopsies 
are collected and scored under the same conditions, 
especially  in  large  cohorts  of  previously  identified 
enriched ALT segments. That aside, the overall spread 
of ALT across the board (see Table 1) was in agree-
ment with previous findings (25,126-135).  
 
 
Table 1: Tumour types in which ALT was detected in this survey, in descending order of prevalence (124,125) (see also 
Figure 2). 
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Figure 2. Malignancies prevalent in ALT. Black text in circles denote sarcomas most prevalent in ALT (>20% of those 
tested on average). Black text in boxes denote the main tumours in which ALT has been detected to a significant degree of 
frequency (>20% of those tested on average). Grey text in boxes indicate subsets where ALT has been detected but to a 
lesser degree (<20% and >4% and these make up the rest of the top-10 most ALT prevalent cancer cases. See text for detailed 
breakdown  of  ALT  in  each  subtype.  (Adapted  from  the  Massachussets  Ganeral  Hospital  sarcoma  website: 
http://www2.massgeneral.org/cancerresourceroom/types/pedi/illustrations/sarcoma.asp) 
 
 
The  accumulated  evidence  from  previous 
studies that have focussed on one particular cancer 
subtype using limited numbers of TMA samples have 
reported  similar  prevalences  of  ALT  as  has  been 
documented  in  this  recent  survey.  However,  a 
particular study highlighted ALT prevelance in 38% 
(17/42) of cases of gastric carcinoma tissues analysed 
(136). This does not seem to be in concordance with  Journal of Cancer 2012, 3 
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Heaphy et al’s survey in which no occurences of ALT 
in  155  samples  of  gastric  adenocarcinoma  were 
detected. This may reflect the fact most samples were 
adenocarcinomas of the stomach and these might not 
utilise ALT as commonly as other gastric carcinomas. 
Omori et al also saw ALT frequency to be even higher 
in  tissues  scored  as  having  microsattelite  instability 
(mismatch repair deficient) although the mechanism 
connecting ALT with MSI is currently unknown. 
Perhaps surprisingly, another recent study  has 
identified a particularly high prevalence of ALT (32%) 
in Wilm’s Tumour (WT) samples (paediatric nephro-
blastoma of the kidney) – one of the most common 
solid  tumours  of  childhood  (137).  Many  paediatric 
tumours over-express telomerase. Thus, many studies 
of  WT  and  other  paediatric  malignancies  have  fo-
cused  on  telomerase  over-activation  (138-140).  This 
paediatric  tumour  seems  to  activate  ALT  quite  fre-
quently. However, since these tumours contain a mix 
of epithelial and  mesenchymal tissue  –  its  gene ex-
pression  profile  resembling  the  earliest  epithelial  to 
mesenchymal transitory (EMT) stage – this prompted 
the authors to investigate ALT in WT which to their 
knowledge had not been done previously. Therefore 
the  mesenchymal  status  of  WT  may  provide  the 
driver for ALT in this disease as previously discussed. 
Alternatively,  a  pattern  may  be  emerging  in  which 
paediatric malignancies may be particular prevalent 
in ALT, recently highlighted in paediatric verses adult 
glioblastoma multiforme (see Table 1). One possible 
reason for this could be that a recent and robust si-
lencing of telomerase activity following embryogene-
sis may provide a vulnerable time frame for ALT to 
take  over  under  such  telomerase  repressed  condi-
tions.  Accordingly,  late  onset  telomerase-positive 
tumours  might  take  advantage  of  gradually  more 
relaxed  telomerase-silencing  mechanisms,  perhaps 
after  an  accumulation  of  precluding  mutations  that 
contribute to telomerase reactivation. It would be in-
teresting to know the ALT prevalence in other ear-
ly-onset paediatric malignancies. 
Figure  2  illustrates  the  most  frequent 
ALT-bearing tumour types currently documented in 
the  literature  and  incorporates  previously  docu-
mented highly prevalent subsets into the findings of 
the most recent and comprehensive survey published 
this year. It represents a large collection of broad tu-
mour types, many of which are rare niche segments 
and others more common, but most tend to have par-
ticularly high unmet medical needs. Therefore, drug 
discovery programs aimed at targeting specific ALT 
components will be of significant clinical value in the 
pursuit of developing personalized healthcare medi-
cines in particularly difficult to treat cancer subsets. 
Concluding remarks 
The pathways and specific components of ALT 
represent extremely attractive targets for therapeutic 
intervention in cancers that thwart telomere erosion 
independently  of  telomerase  activity.  To  this  end, 
factors such as redundancy and telomerase reactiva-
tion must be considered as possible challenges in the 
future.  However,  the  rapid  shortening  of  telomeres 
seen when ALT is inhibited in ALT-positive tumour 
cell lines and the clear steer towards specific tumour 
types prevalent in ALT provide exciting therapeutic 
opportunities with defined lines of site to the clinic. 
As more studies that focus on the specific mechanisms 
involved in ALT help us to understand exactly why 
certain tumours become dependent on it for survival, 
we  will  move  ever  closer  to  developing  effective 
therapies designed to deliver mortal blows to these 
specific cancers subtypes. 
Acknowledgements 
I would like to thank Nicol Keith, Alan Meeker, 
Roger Reddel and Sheila Stewart for helpful insights 
and regret not being able to include all studies perti-
nent to this broad and important area of research. 
Conflict of Interest 
The authors have declared that no conflict of in-
terest exists. 
References 
1.  Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, 
Jones MD, et al. A highly conserved repetitive DNA sequence, 
(TTAGGG)n, present at the telomeres of human chromosomes. 
Proc.Natl.Acad.Sci.U.S.A. 1988 Sep;85(18):6622-6626.  
2.  Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, 
Moss H, et al. Mammalian telomeres end in a large duplex loop. 
Cell 1999 May 14;97(4):503-514. 
3.  Vaziri H, Benchimol S. From telomere loss to p53 induction and 
activation of a DNA-damage pathway at senescence: the telo-
mere  loss/DNA  damage  model  of  cell  aging.  Exp.Gerontol. 
1996;31(1-2):295-301.  
4.  Shay  JW,  Wright  WE.  Telomerase  activity  in  human  cancer. 
Curr.Opin.Oncol. 1996 Jan;8(1):66-71.  
5.  Harley CB. Telomere loss: mitotic clock or genetic time bomb? 
Mutat.Res. 1991;256(2-6):271-282.  
6.  Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, 
Lansdorp PM. Evidence for a mitotic clock in human hemato-
poietic  stem  cells:  loss  of  telomeric  DNA  with  age. 
Proc.Natl.Acad.Sci.U.S.A. 1994 Oct 11;91(21):9857-9860.  
7.  d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, 
Carr P, Von Zglinicki T, et al. A DNA damage checkpoint re-
sponse  in  telomere-initiated  senescence.  Nature  2003  Nov 
13;426(6963):194-198.  
8.  Blackburn EH, Greider CW, Henderson E, Lee MS, Shampay J, 
Shippen-Lentz D. Recognition and elongation of telomeres by 
telomerase. Genome 1989;31(2):553-560.  
9.  Cesare  AJ,  Reddel  RR.  Telomere  uncapping  and  alternative 
lengthening  of  telomeres.  Mech.  Ageing  Dev. 
2008;129(1-2):99-108.   Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
79 
10.  Cesare  AJ, Reddel  RR.  Alternative  lengthening  of  telomeres: 
models,  mechanisms  and  implications.  Nat.Rev.Genet.  2010 
May;11(5):319-330.  
11.  Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Te-
lomerase  activity  in  human  germline  and  embryonic  tissues 
and cells. Dev.Genet. 1996;18(2):173-179.  
12.  Ulaner GA, Giudice LC. Developmental regulation of telomer-
ase  activity  in  human  fetal  tissues  during  gestation. 
Mol.Hum.Reprod. 1997 Sep;3(9):769-773.  
13.  Reddel  RR,  Bryan  TM,  Colgin  LM,  Perrem  KT,  Yeager  TR. 
Alternative  lengthening  of  telomeres  in  human  cells.  Radi-
at.Res. 2001 Jan;155(1 Pt 2):194-200.  
14.  Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, 
Robinson RA, et al. A robust assay for alternative lengthening 
of  telomeres  in  tumors  shows  the  significance  of  alternative 
lengthening  of  telomeres  in  sarcomas  and  astrocytomas. 
Clin.Cancer Res. 2005 Jan 1;11(1):217-225.  
15.  Shay JW, Wright WE. The reactivation of telomerase activity in 
cancer progression. Trends Genet. 1996 Apr;12(4):129-131.  
16.  Holt SE, Wright WE, Shay JW. Regulation of telomerase activity 
in immortal cell lines. Mol.Cell.Biol. 1996 Jun;16(6):2932-2939.  
17.  Molckovsky  A,  Siu  LL.  First-in-class,  first-in-human  phase  I 
results of targeted agents: highlights of the 2008 American so-
ciety of clinical oncology meeting. J.Hematol.Oncol. 2008 Oct 
29;1:20.  
18.  Roth  A,  Harley  CB,  Baerlocher  GM.  Imetelstat 
(GRN163L)--telomerase-based  cancer  therapy.  Recent  Results 
Cancer Res. 2010;184:221-234.  
19.  Ouellette  MM,  Wright  WE,  Shay  JW.  Targeting  telomer-
ase-expressing  cancer  cells.  J.Cell.Mol.Med.  2011 
Jul;15(7):1433-1442.  
20.  Buseman  CM,  Wright  WE,  Shay  JW.  Is  telomerase  a  viable 
target in cancer? Mutat.Res. 2012 Feb 1;730(1-2):90-7.  
21.  Ouellette  MM,  Wright  WE,  Shay  JW.  Targeting  telomer-
ase-expressing  cancer  cells.  J.Cell.Mol.Med.  2011 
Jul;15(7):1433-1442.  
22.  Sidorov IA, Hirsch KS, Harley CB, Dimitrov DS. Cancer treat-
ment by telomerase inhibitors: predictions by a kinetic model. 
Math.Biosci. 2003 Feb;181(2):209-221.  
23.  Folini  M,  Gandellini  P,  Zaffaroni  N.  Targeting  the  telosome: 
therapeutic  implications.  Biochim.Biophys.Acta  2009 
Apr;1792(4):309-316.  
24.  Siddiqa A, Cavazos DA, Marciniak RA. Targeting telomerase. 
Rejuvenation Res. 2006;9(3):378-390.  
25.  Cesare  AJ, Reddel  RR.  Alternative  lengthening  of  telomeres: 
models,  mechanisms  and  implications.  Nat.Rev.Genet.  2010 
May;11(5):319-330.  
26.  Royle NJ, Mendez-Bermudez A, Gravani A, Novo C, Foxon J, 
Williams J, et al. The role of recombination in telomere length 
maintenance. Biochem.Soc.Trans. 2009 Jun;37(Pt 3):589-595.  
27.  Saharia A, Stewart SA. FEN1 contributes to telomere stability in 
ALT-positive  tumor  cells.  Oncogene  2009  Feb 
26;28(8):1162-1167.  
28.  Zeng S, Yang Q. The MUS81 endonuclease is essential for te-
lomerase  negative  cell  proliferation.  Cell.Cycle  2009  Jul 
15;8(14):2157-2160.  
29.   Zeng S, Xiang T, Pandita TK, Gonzalez-Suarez I, Gonzalo S, 
Harris CC, et al. Telomere recombination requires the MUS81 
endonuclease. Nat.Cell Biol. 2009 May;11(5):616-623.  
30.  Temime-Smaali N, Guittat L, Sidibe A, Shin-ya K, Trentesaux C, 
Riou JF. The G-quadruplex ligand telomestatin impairs binding 
of  topoisomerase  IIIalpha  to  G-quadruplex-forming  oligonu-
cleotides and uncaps telomeres in ALT cells. PLoS One 2009 Sep 
9;4(9):e6919.  
31.  Patel DJ, Phan AT, Kuryavyi V. Human telomere, oncogenic 
promoter  and  5'-UTR  G-quadruplexes:  diverse  higher  order 
DNA and RNA targets for cancer therapeutics. Nucleic Acids 
Res. 2007;35(22):7429-7455.  
32.  Huppert JL, Balasubramanian S. G-quadruplexes in promoters 
throughout  the  human  genome.  Nucleic  Acids  Res. 
2007;35(2):406-413.  
33.  Huppert  JL.  Four-stranded  nucleic  acids:  structure,  function 
and  targeting  of  G-quadruplexes.  Chem.Soc.Rev.  2008 
Jul;37(7):1375-1384.  
34.  Huppert  JL.  Structure,  location  and  interactions  of 
G-quadruplexes. FEBS J. 2010 Sep;277(17):3452-3458.  
35.  Cerone  MA,  Londono-Vallejo  JA,  Bacchetti  S.  Telomere 
maintenance by telomerase and by recombination can coexist in 
human cells. Hum.Mol.Genet. 2001 Sep 1;10(18):1945-1952.  
36.  Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, 
Shay  JW.  Correlating  telomerase  activity  levels  with  human 
neuroblastoma outcomes. Nat.Med. 1995 Mar;1(3):249-255.  
37.  Hiyama E, Hiyama K, Nishiyama M, Reynolds CP, Shay JW, 
Yokoyama  T.  Differential  gene  expression  profiles  between 
neuroblastomas  with  high  telomerase  activity  and  low  te-
lomerase activity. J.Pediatr.Surg. 2003 Dec;38(12):1730-1734.  
38.  Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telo-
mere elongation in immortal human cells without detectable 
telomerase activity. EMBO J. 1995 Sep 1;14(17):4240-4248.  
39.  Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble 
JR, Reddel RR. Telomerase-negative immortalized human cells 
contain a novel type of promyelocytic leukemia (PML) body. 
Cancer Res. 1999 Sep 1;59(17):4175-4179.  
40.  Henson JD, Reddel RR. Assaying and investigating Alternative 
Lengthening of Telomeres activity in human cells and cancers. 
FEBS Lett. 2010 Sep 10;584(17):3800-3811.  
41.  Greider CW, Blackburn EH. Identification of a specific telomere 
terminal transferase activity in Tetrahymena extracts. Cell 1985 
Dec;43(2 Pt 1):405-413.  
42.  Greider CW, Blackburn EH. The telomere terminal transferase 
of Tetrahymena is a ribonucleoprotein enzyme with two kinds 
of primer specificity. Cell 1987 Dec 24;51(6):887-898.  
43.  Greider CW, Blackburn EH. A telomeric sequence in the RNA 
of Tetrahymena telomerase required for telomere repeat syn-
thesis. Nature 1989 Jan 26;337(6205):331-337.  
44.  Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho 
PL, et al. Specific association of human telomerase activity with 
immortal  cells  and  cancer.  Science  1994  Dec 
23;266(5193):2011-2015.  
45.  Xin H. Telomeric repeat amplification protocol: measuring the 
activity of the telomerase. Methods Mol.Biol. 2011;735:107-111.  
46.  Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et 
al. Altered telomeres in tumors with ATRX and DAXX muta-
tions. Science 2011 Jul 22;333(6041):425.  
47.  Lundblad V, Blackburn EH. An alternative pathway for yeast 
telomere maintenance rescues est1- senescence. Cell 1993 Apr 
23;73(2):347-360.  
48.  Teng SC, Zakian VA. Telomere-telomere recombination is an 
efficient bypass pathway for telomere maintenance in Saccha-
romyces cerevisiae. Mol.Cell.Biol. 1999 Dec;19(12):8083-8093.  
49.  Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telo-
mere maintenance by recombination in human cells. Nat.Genet. 
2000 Dec;26(4):447-450.  
50.  Bailey SM, Brenneman MA, Goodwin EH. Frequent recombi-
nation in telomeric DNA may extend the proliferative life of 
telomerase-negative  cells.  Nucleic  Acids  Res.  2004  Jul 
16;32(12):3743-3751.  
51.  Royle NJ, Foxon J, Jeyapalan JN, Mendez-Bermudez A, Novo 
CL, Williams J, et al. Telomere length maintenance--an ALTer-
native  mechanism.  Cytogenet.Genome  Res. 
2008;122(3-4):281-291.  
52.  Pickett  HA,  Henson  JD,  Au  AY,  Neumann  AA,  Reddel  RR. 
Normal mammalian cells negatively regulate telomere length  Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
80 
by  telomere  trimming.  Hum.Mol.Genet.  2011  Dec 
1;20(23):4684-4692.  
53.  Verdun  RE,  Crabbe  L,  Haggblom  C,  Karlseder  J.  Functional 
human telomeres are recognized as DNA damage in G2 of the 
cell cycle. Mol.Cell 2005 Nov 23;20(4):551-561.  
54.  De  Boeck  G,  Forsyth  RG,  Praet  M,  Hogendoorn  PC.  Telo-
mere-associated proteins: cross-talk between telomere mainte-
nance  and  telomere-lengthening  mechanisms.  J.Pathol.  2009 
Feb;217(3):327-344.  
55.  Durant ST, Paffett KS, Shrivastav M, Timmins GS, Morgan WF, 
Nickoloff JA. UV radiation induces delayed hyperrecombina-
tion  associated  with  hypermutation  in  human  cells. 
Mol.Cell.Biol. 2006 Aug;26(16):6047-6055.  
56.  Tanaka H, Mendonca MS, Bradshaw PS, Hoelz DJ, Malkas LH, 
Meyn MS, et al. DNA damage-induced phosphorylation of the 
human  telomere-associated  protein  TRF2. 
Proc.Natl.Acad.Sci.U.S.A. 2005 Oct 25;102(43):15539-15544.  
57.  Huda  N,  Tanaka  H,  Mendonca  MS,  Gilley  D.  DNA  dam-
age-induced phosphorylation of TRF2 is required for the fast 
pathway  of  DNA  double-strand  break  repair.  Mol.Cell.Biol. 
2009 Jul;29(13):3597-3604.  
58.  Vousden  KH,  Lane  DP.  P53  in  Health  and  Disease. 
Nat.Rev.Mol.Cell Biol. 2007 Apr;8(4):275-283.  
59.  Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kess-
ler B, et al. Arginine methylation regulates the p53 response. 
Nat.Cell Biol. 2008 Dec;10(12):1431-1439.  
60.  Durant  ST,  Cho  EC,  La  Thangue  NB.  p53  methylation--the 
Arg-ument is clear. Cell.Cycle 2009 Mar 15;8(6):801-802.  
61.  Vaziri  H,  West  MD,  Allsopp  RC,  Davison  TS,  Wu  YS,  Ar-
rowsmith  CH,  et  al.  ATM-dependent  telomere  loss  in  aging 
human  diploid  fibroblasts  and  DNA  damage  lead  to  the 
post-translational  activation  of  p53  protein  involving 
poly(ADP-ribose)  polymerase.  EMBO  J.  1997  Oct 
1;16(19):6018-6033.  
62.  Dantzer F, Giraud-Panis MJ, Jaco I, Ame JC, Schultz I, Blasco M, 
et al. Functional interaction between poly(ADP-Ribose) poly-
merase 2 (PARP-2) and TRF2: PARP activity negatively regu-
lates TRF2. Mol.Cell.Biol. 2004 Feb;24(4):1595-1607.  
63.  Jiang WQ, Zhong ZH, Henson JD, Neumann AA, Chang AC, 
Reddel RR. Suppression of alternative lengthening of telomeres 
by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 
complex. Mol.Cell.Biol. 2005 Apr;25(7):2708-2721.  
64.  Lee  JH,  Paull  TT.  Activation  and  regulation  of  ATM  kinase 
activity in response to DNA double-strand breaks. Oncogene 
2007 Dec 10;26(56):7741-7748.  
65.  Wu Y, Xiao S, Zhu XD. MRE11-RAD50-NBS1 and ATM func-
tion  as  co-mediators  of  TRF1  in  telomere  length  control. 
Nat.Struct.Mol.Biol. 2007 Sep;14(9):832-840.  
66.   Zhong ZH, Jiang WQ, Cesare AJ, Neumann AA, Wadhwa R, 
Reddel RR. Disruption of telomere maintenance by depletion of 
the MRE11/RAD50/NBS1 complex in cells that use alternative 
lengthening  of  telomeres.  J.Biol.Chem.  2007  Oct 
5;282(40):29314-29322.  
67.  Celli  GB,  Denchi  EL, de Lange T. Ku70  stimulates  fusion of 
dysfunctional  telomeres  yet  protects  chromosome  ends  from 
homologous  recombination.  Nat.Cell  Biol.  2006 
Aug;8(8):885-890.  
68.  Bodvarsdottir  SK,  Steinarsdottir  M,  Bjarnason  H,  Eyfjord  JE. 
Dysfunctional telomeres in human BRCA2 mutated breast tu-
mors and cell lines. Mutat.Res. 2012 Jan 3;729(1-2):90-9.  
69.  French JD, Dunn J, Smart CE, Manning N, Brown MA. Disrup-
tion of BRCA1 function results in telomere lengthening and in-
creased anaphase bridge formation in immortalized cell lines. 
Genes Chromosomes Cancer 2006 Mar;45(3):277-289.  
70.  Li  B,  Reddy  S,  Comai  L.  Depletion  of  Ku70/80  reduces  the 
levels of extrachromosomal telomeric circles and inhibits pro-
liferation  of  ALT  cells.  Aging  (Albany  NY)  2011 
Apr;3(4):395-406.  
71.  Liu Y, Tarsounas M, O'regan P, West SC. Role of RAD51C and 
XRCC3 in genetic recombination and DNA repair. J.Biol.Chem. 
2007 Jan 19;282(3):1973-1979.  
72.  Ding H, Schertzer M, Wu X, Gertsenstein M, Selig S, Kammori 
M, et al. Regulation of murine telomere length by Rtel: an es-
sential  gene  encoding  a  helicase-like  protein.  Cell  2004  Jun 
25;117(7):873-886.  
73.  Durant ST, Nickoloff JA. Good timing in the cell cycle for pre-
cise DNA repair by BRCA1. Cell.Cycle 2005 Sep;4(9):1216-1222.  
74.  Durant ST, Paffett KS, Shrivastav M, Timmins GS, Morgan WF, 
Nickoloff JA. UV radiation induces delayed hyperrecombina-
tion  associated  with  hypermutation  in  human  cells. 
Mol.Cell.Biol. 2006 Aug;26(16):6047-6055.  
75.  Shrivastav M, Miller CA, De Haro LP, Durant ST, Chen BP, 
Chen DJ,  et  al. DNA-PKcs and ATM  co-regulate DNA  dou-
ble-strand  break  repair.  DNA  Repair  (Amst)  2009  Aug 
6;8(8):920-929.  
76.  Lee  SH,  Oshige  M,  Durant  ST,  Rasila  KK,  Williamson  EA, 
Ramsey H, et al. The SET domain protein Metnase mediates 
foreign DNA integration and links integration to nonhomolo-
gous  end-joining  repair.  Proc.Natl.Acad.Sci.U.S.A.  2005  Dec 
13;102(50):18075-18080.  
77.  De Haro LP,  Wray  J,  Williamson  EA, Durant  ST, Corwin L, 
Gentry AC, et al. Metnase promotes restart and repair of stalled 
and  collapsed  replication  forks.  Nucleic  Acids  Res.  2010 
Sep;38(17):5681-5691.  
78.  MacKay  C,  Declais  AC,  Lundin  C,  Agostinho  A,  Deans  AJ, 
MacArtney TJ, et al. Identification of KIAA1018/FAN1, a DNA 
repair  nuclease  recruited  to  DNA  damage  by  monoubiqui-
tinated FANCD2. Cell 2010 Jul 9;142(1):65-76.  
79.  Yamamoto KN, Kobayashi S, Tsuda M, Kurumizaka H, Takata 
M, Kono K, et al. Involvement of SLX4 in interstrand cross-link 
repair  is  regulated  by  the  Fanconi  anemia  pathway. 
Proc.Natl.Acad.Sci.U.S.A. 2011 Apr 19;108(16):6492-6496.  
80.  Zhu XD, Niedernhofer L, Kuster B, Mann M, Hoeijmakers JH, 
de Lange T. ERCC1/XPF removes the 3' overhang from un-
capped  telomeres  and  represses  formation  of  telomeric 
DNA-containing double minute chromosomes. Mol.Cell 2003 
Dec;12(6):1489-1498.  
81.  Chen XB, Melchionna R, Denis CM, Gaillard PH, Blasina A, Van 
de  Weyer  I,  et  al.  Human  Mus81-associated  endonuclease 
cleaves  Holliday  junctions  in  vitro.  Mol.Cell  2001 
Nov;8(5):1117-1127.  
82.  Boddy MN, Gaillard PH, McDonald WH, Shanahan P, Yates 
JR,3rd, Russell P. Mus81-Eme1 are essential components of a 
Holliday junction resolvase. Cell 2001 Nov 16;107(4):537-548.  
83.  Osman  F,  Whitby  MC.  Exploring  the  roles  of 
Mus81-Eme1/Mms4 at perturbed replication forks. DNA Re-
pair (Amst) 2007 Jul 1;6(7):1004-1017.  
84.  Tsutakawa SE, Classen S, Chapados BR, Arvai AS, Finger LD, 
Guenther G, et al. Human flap endonuclease structures, DNA 
double-base flipping, and a unified understanding of the FEN1 
superfamily. Cell 2011 Apr 15;145(2):198-211.  
85.  Zheng L, Shen B. Okazaki fragment maturation: nucleases take 
centre stage. J.Mol.Cell.Biol. 2011 Feb;3(1):23-30.  
86.  Liu Y, Kao HI,  Bambara  RA.  Flap  endonuclease 1: a central 
component  of  DNA  metabolism.  Annu.Rev.Biochem. 
2004;73:589-615.  
87.  Crabbe  L,  Verdun  RE,  Haggblom  CI,  Karlseder  J.  Defective 
telomere lagging strand synthesis in cells lacking WRN helicase 
activity. Science 2004 Dec 10;306(5703):1951-1953.  
88.  Eller MS, Liao X, Liu S, Hanna K, Backvall H, Opresko PL, et al. 
A  role  for  WRN  in  telomere-based  DNA  damage  responses. 
Proc.Natl.Acad.Sci.U.S.A. 2006 Oct 10;103(41):15073-15078.   Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
81 
89.  Opresko  PL,  Sowd  G,  Wang  H.  The  Werner  syndrome  hel-
icase/exonuclease  processes  mobile  D-loops  through  branch 
migration and degradation. PLoS One 2009;4(3):e4825.  
90.  Kusumoto-Matsuo R, Opresko PL, Ramsden D, Tahara H, Bohr 
VA.  Cooperation  of  DNA-PKcs  and  WRN  helicase  in  the 
maintenance  of  telomeric  D-loops.  Aging  (Albany  NY)  2010 
May;2(5):274-284.  
91.  Laud PR, Multani AS, Bailey SM, Wu L, Ma J, Kingsley C, et al. 
Elevated  telomere-telomere  recombination  in  WRN-deficient, 
telomere dysfunctional cells promotes escape from senescence 
and engagement of the ALT pathway. Genes Dev. 2005 Nov 
1;19(21):2560-2570.  
92.  Noel JF, Wellinger RJ. The Smc5/6 complex and the difficulties 
cutting  the  ties  of  twin  sisters.  Aging  (Albany  NY)  2011 
Mar;3(3):186-188.  
93.  Potts  PR,  Yu  H.  The  SMC5/6  complex  maintains  telomere 
length  in  ALT  cancer  cells  through  SUMOylation  of  telo-
mere-binding  proteins.  Nat.Struct.Mol.Biol.  2007 
Jul;14(7):581-590.  
94.  Chavez A, George V, Agrawal V, Johnson FB. Sumoylation and 
the structural maintenance of chromosomes (Smc) 5/6 complex 
slow  senescence  through  recombination  intermediate  resolu-
tion. J.Biol.Chem. 2010 Apr 16;285(16):11922-11930.  
95.  Grewal  SI,  Jia  S.  Heterochromatin  revisited.  Nat.Rev.Genet. 
2007 Jan;8(1):35-46.  
96.  Nguyen  AT,  Zhang  Y.  The  diverse  functions  of  Dot1  and 
H3K79 methylation. Genes Dev. 2011 Jul 1;25(13):1345-1358.  
97.  Norris A, Boeke JD. Silent information regulator 3: the Goldi-
locks  of  the  silencing  complex.  Genes  Dev.  2010  Jan 
15;24(2):115-122.  
98.  Gonzalo S, Jaco I, Fraga MF, Chen T, Li E, Esteller M, et al. DNA 
methyltransferases  control  telomere  length  and  telomere  re-
combination  in  mammalian  cells.  Nat.Cell  Biol.  2006 
Apr;8(4):416-424.  
99.  Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, 
Park  SK,  et  al.  SIRT1  redistribution  on  chromatin  promotes 
genomic stability but alters gene expression during aging. Cell 
2008 Nov 28;135(5):907-918.  
100.  Vaitiekunaite  R,  Butkiewicz  D,  Krzesniak  M,  Przybylek  M, 
Gryc A, Snietura M, et al. Expression and localization of Werner 
syndrome  protein  is  modulated  by  SIRT1  and  PML. 
Mech.Ageing Dev. 2007;128(11-12):650-661.  
101.  Kahyo T, Mostoslavsky R, Goto M, Setou M. Sirtuin-mediated 
deacetylation  pathway  stabilizes  Werner  syndrome  protein. 
FEBS Lett. 2008 Jul 23;582(17):2479-2483.  
102.  Sakao Y, Kato A, Tsuji T, Yasuda H, Togawa A, Fujigaki Y, et al. 
Cisplatin induces Sirt1 in association with histone deacetylation 
and  increased  Werner  syndrome  protein  in  the  kidney. 
Clin.Exp.Nephrol. 2011 Jun;15(3):363-372.  
103.  Yuan Z, Zhang X, Sengupta N, Lane WS, Seto E. SIRT1 regu-
lates the function of the Nijmegen breakage syndrome protein. 
Mol.Cell 2007 Jul 6;27(1):149-162.  
104.  Yuan Z, Seto E. A functional link between SIRT1 deacetylase 
and  NBS1  in  DNA  damage  response.  Cell.Cycle  2007  Dec 
1;6(23):2869-2871.  
105.  Lim DS, Kim ST, Xu B, Maser RS, Lin J, Petrini JH, et al. ATM 
phosphorylates p95/nbs1 in an S-phase checkpoint pathway. 
Nature 2000 Apr 6;404(6778):613-617.  
106.  Palacios JA, Herranz D, De Bonis ML, Velasco S, Serrano M, 
Blasco  MA.  SIRT1  contributes  to  telomere  maintenance  and 
augments global homologous recombination. J.Cell Biol. 2010 
Dec 27;191(7):1299-1313.  
107.  Law  MJ,  Lower  KM,  Voon  HP,  Hughes  JR,  Garrick  D, 
Viprakasit V, et al. ATR-X syndrome  protein targets tandem 
repeats  and  influences  allele-specific  expression  in  a 
size-dependent manner. Cell 2010 Oct 29;143(3):367-378.  
108.  Goldberg AD, Banaszynski LA, Noh KM, Lewis PW, Elsaesser 
SJ, Stadler S, et al. Distinct factors control histone variant H3.3 
localization  at  specific  genomic  regions.  Cell  2010  Mar 
5;140(5):678-691.  
109.  Wong LH, McGhie JD, Sim M, Anderson MA, Ahn S, Hannan 
RD, et al. ATRX interacts with H3.3 in maintaining telomere 
structural  integrity  in  pluripotent  embryonic  stem  cells.  Ge-
nome Res. 2010 Mar;20(3):351-360.  
110.  Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone 
MG, Zaffaroni N, et al. A gene expression signature classifying 
telomerase and ALT immortalization reveals an hTERT regu-
latory network and suggests a mesenchymal stem cell origin for 
ALT. Oncogene 2009 Oct 29;28(43):3765-3774.  
111.  Xue Y, Li L, Zhang D, Wu K, Chen Y, Zeng J, et al. Twisted 
Epithelial-to-Mesenchymal Transition Promotes Progression of 
Surviving Bladder Cancer T24 Cells with hTERT-Dysfunction. 
PLoS One 2011;6(11):e27748.  
112.  Stiller D, Path FW, Kaiser HE. Some characteristics of the mes-
enchymal  stem  cell  of  soft  tissue  tumors.  In  Vivo 
1992;6(4):477-480.  
113.  Atkinson SP, Hoare SF, Glasspool RM, Keith WN. Lack of te-
lomerase gene expression in alternative lengthening of telomere 
cells is associated with chromatin remodeling of the hTR and 
hTERT  gene  promoters.  Cancer  Res.  2005  Sep 
1;65(17):7585-7590.  
114.  Lafferty-Whyte K, Cairney CJ, Will MB, Serakinci N, Daidone 
MG, Zaffaroni N, et al. A gene expression signature classifying 
telomerase and ALT immortalization reveals an hTERT regu-
latory network and suggests a mesenchymal stem cell origin for 
ALT. Oncogene 2009 Oct 29;28(43):3765-3774.  
115.  Hao H, Nancai Y, Lei F, Xiong W, Wen S, Guofu H, et al. siRNA 
directed  against  c-Myc  inhibits  proliferation  and  downregu-
lates human telomerase reverse transcriptase in human colon 
cancer Colo 320 cells. J.Exp.Clin.Cancer Res. 2008 Aug 12;27:27.  
116.  Chang M, Dittmar JC, Rothstein R. Long telomeres are prefer-
entially  extended  during  recombination-mediated  telomere 
maintenance. Nat.Struct.Mol.Biol. 2011 Apr;18(4):451-456.  
117.  Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et 
al. Altered telomeres in tumors with ATRX and DAXX muta-
tions. Science 2011 Jul 22;333(6041):425.  
118.  McDonald KL, McDonnell J, Muntoni A, Henson JD, Hegi ME, 
von Deimling A, et al. Presence of alternative lengthening of 
telomeres mechanism in patients with glioblastoma identifies a 
less  aggressive  tumor  type  with  longer  survival. 
J.Neuropathol.Exp.Neurol. 2010 Jul;69(7):729-736.  
119.  Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, et al. 
Telomere  maintenance  mechanisms  in  liposarcomas:  associa-
tion with histologic subtypes and disease progression. Cancer 
Res. 2006 Sep 1;66(17):8918-8924.  
120.  Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative 
lengthening of telomeres in mammalian cells. Oncogene 2002 
Jan 21;21(4):598-610.  
121.  Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Van-
nelli A, et al. Multiple mechanisms of telomere maintenance 
exist and differentially affect clinical outcome in diffuse ma-
lignant  peritoneal  mesothelioma.  Clin.Cancer  Res.  2008  Jul 
1;14(13):4134-4140.  
122.  Subhawong AP, Heaphy CM, Argani P, Konishi Y, Kouprina N, 
Nassar H, et al. The alternative lengthening of telomeres phe-
notype in breast carcinoma is associated with HER-2 overex-
pression. Mod.Pathol. 2009 Nov;22(11):1423-1431.  
123.  Venturini L, Erdas R, Costa A, Gronchi A, Pilotti S, Zaffaroni N, 
et al. ALT-associated promyelocytic leukaemia body (APB) de-
tection as a reproducible tool to assess alternative lengthening 
of  telomere  stability  in  liposarcomas.  J.Pathol.  2008 
Mar;214(4):410-414.   Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
82 
124.  Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Mont-
gomery EA, Gabrielson E, et al. Prevalence of the alternative 
lengthening of telomeres telomere maintenance mechanism in 
human  cancer  subtypes.  Am.J.Pathol.  2011 
Oct;179(4):1608-1615.  
125.  Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et 
al. Altered telomeres in tumors with ATRX and DAXX muta-
tions. Science 2011 Jul 22;333(6041):425.  
126.  Silvestre DC, Pineda JR, Hoffschir F, Studler JM, Mouthon MA, 
Pflumio F, et al. Alternative lengthening of telomeres in human 
glioma stem cells. Stem Cells 2011 Mar;29(3):440-451.  
127.  Lundberg G, Sehic D, Lansberg JK, Ora I, Frigyesi A, Castel V, 
et al. Alternative lengthening of telomeres--an enhanced chro-
mosomal  instability  in  aggressive  non-MYCN  amplified  and 
telomere  elongated  neuroblastomas.  Genes  Chromosomes 
Cancer 2011 Apr;50(4):250-262.  
128.  Au AY, Hackl T, Yeager TR, Cohen SB, Pass HI, Harris CC, et al. 
Telomerase activity in pleural malignant mesotheliomas. Lung 
Cancer 2011 Sep;73(3):283-288.  
129.  Lundberg G, Sehic D, Lansberg JK, Ora I, Frigyesi A, Castel V, 
et al. Alternative lengthening of telomeres--an enhanced chro-
mosomal  instability  in  aggressive  non-MYCN  amplified  and 
telomere  elongated  neuroblastomas.  Genes  Chromosomes 
Cancer 2011 Apr;50(4):250-262.  
130.  Venturini  L,  Motta  R,  Gronchi  A,  Daidone  M,  Zaffaroni  N. 
Prognostic  relevance  of  ALT-associated  markers  in  liposar-
coma: a comparative analysis. BMC Cancer 2010 Jun 3;10:254.  
131.  Henson JD, Reddel RR. Assaying and investigating Alternative 
Lengthening of Telomeres activity in human cells and cancers. 
FEBS Lett. 2010 Sep 10;584(17):3800-3811.  
132.  Slatter T, Gifford-Garner J, Wiles A, Tan X, Chen YJ, MacFar-
lane M, et al. Pilocytic astrocytomas have telomere-associated 
promyelocytic  leukemia  bodies  without  alternatively  length-
ened telomeres. Am.J.Pathol. 2010 Dec;177(6):2694-2700.  
133.  Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Ochi M. 
Alternative lengthening of telomeres as a prognostic factor in 
malignant fibrous histiocytomas of bone. Anticancer Res. 2010 
Dec;30(12):4959-4962.  
134.  Yamamoto Y, Yamamoto N, Tajima K, Ohno A, Washimi Y, 
Ishimura D, et al. Characterization of human multicentric os-
teosarcoma using newly established cells derived from multi-
centric  osteosarcoma.  J.Cancer  Res.Clin.Oncol.  2011 
Mar;137(3):423-433.  
135.  Lundberg G, Sehic D, Lansberg JK, Ora I, Frigyesi A, Castel V, 
et al. Alternative lengthening of telomeres-An enhanced chro-
mosomal  instability  in  aggressive  non-MYCN  amplified  and 
telomere  elongated  neuroblastomas.  Genes  Chromosomes 
Cancer 2011 Apr;50(4):250-62.  
136.  Omori Y, Nakayama F, Li D, Kanemitsu K, Semba S, Ito A, et al. 
Alternative  lengthening  of  telomeres  frequently  occurs  in 
mismatch repair system-deficient gastric carcinoma. Cancer.Sci. 
2009 Mar;100(3):413-418.  
137.  Venturini L, Daidone MG, Motta R, Collini P, Spreafico F, Ter-
enziani M, et al. Telomere maintenance in Wilms tumors: first 
evidence  for  the  presence  of  alternative  lengthening  of  telo-
meres  mechanism.  Genes  Chromosomes  Cancer  2011 
Oct;50(10):823-829.  
138.  Dome JS, Chung S, Bergemann T, Umbricht CB, Saji M, Carey 
LA, et al. High telomerase reverse transcriptase (hTERT) mes-
senger RNA level correlates with tumor recurrence in patients 
with favorable histology Wilms' tumor. Cancer Res. 1999 Sep 
1;59(17):4301-4307.  
139.  Dome JS, Bockhold CA, Li SM, Baker SD, Green DM, Perlman 
EJ, et al. High telomerase RNA expression level is an adverse 
prognostic  factor  for  favorable-histology  Wilms'  tumor. 
J.Clin.Oncol. 2005 Dec 20;23(36):9138-9145.  
140.  Wittmann S, Wunder C, Zirn B, Furtwangler R, Wegert J, Graf 
N,  et al.  New  prognostic  markers  revealed  by  evaluation of 
genes  correlated  with  clinical  parameters  in  Wilms  tumors. 
Genes Chromosomes Cancer 2008 May;47(5):386-395. 